Madrigal Pharmaceuticals Inc (MDGL)

Madrigal Pharmaceuticals, Inc. (MDGL) saw a 7.92% drop to $175.34 as it announced an inducement grant to Bill Sibold on September 11, 2023, upon his appointment as the new President and CEO. This grant, approved under the 2023 Inducement Plan, included time-based restricted stock units and performance-based restricted stock units. Additionally, eight other new employees were granted inducement awards under the same plan on September 14, 2023.

https://finance.yahoo.com/news/madrigal-pharmaceuticals-reports-inducement-grants-203000140.html

Madrigal Pharmaceuticals, Inc. (MDGL) experienced a 5.90% decline in its stock today following the announcement of Bill Sibold taking over as Chief Executive Officer (CEO), replacing Paul Friedman, M.D. Dr. Friedman, who held the CEO position since 2016, will remain a member of Madrigal's Board of Directors.

https://www.globenewswire.com/news-release/2023/09/11/2740645/0/en/Madrigal-Pharmaceuticals-Appoints-Bill-Sibold-as-Chief-Executive-Officer.html

Shares of Madrigal Pharmaceuticals (MDGL) traded down 13.32% today after the announcement that Voya Investment Management LLC grew stocks holdings in the company by 288% in the 4th quarter. Other institutional investors, such as Liberty One Investment Management LLC, EWG Elevate Inc., BNP parisba Arbitrage SA, Miracle Mile Advisors and High Tower Advisors LLC - also recently bought and sold shares of the company. Now that 75.68% of the stock is currently owned by hedge funds and other institutional investors.

https://www.marketbeat.com/instant-alerts/nasdaq-mdgl-sec-filing-2023-06-27/